3131 - 3140 of 9140 Results
Title
Year
-
OPENTitle: Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variantsJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 101Issue #:Start Page: 43End Page: 48Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2022.06.021Best OA location URL: http://www.prd-journal.com/article/S1353802022002176/pdfCitation Count: 11
- Tracer development for PET imaging of proteinopathies2022RESTRICTEDTitle: Tracer development for PET imaging of proteinopathiesJournal Name: Nuclear Medicine and BiologyPublisher: Elsevier BVVol: 114-115Issue #:Start Page: 137End Page: 147Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.nucmedbio.2022.04.001Citation Count: 0
- Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approach2022RESTRICTEDTitle: Deciphering the molecular mechanism and crosstalk between Parkinson's disease and breast cancer through multi-omics and drug repurposing approachJournal Name: NeuropeptidesPublisher: Elsevier BVVol: 96Issue #:Start Page: 102283End Page: 102283Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.npep.2022.102283Citation Count: 11
-
OPENTitle: Duration of benefit per Dose: Carbidopa-Levodopa immediate release vs. extended release capsules (Rytary®)Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 82Issue #:Start Page: 133End Page: 137Publication Date:Open Access(OA) Status: OPENLicense: cc-by-nc-ndDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.002Best OA location URL: http://www.prd-journal.com/article/S1353802020309007/pdfCitation Count: 7
-
OPENTitle: Long-term safety and efficacy of apomorphine infusion in Parkinson's disease patients with persistent motor fluctuations: Results of the open-label phase of the TOLEDO studyJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 83Issue #:Start Page: 79End Page: 85Publication Date:Open Access(OA) Status: OPENLicense: cc-byDOI - Digital Object Identifier: 10.1016/j.parkreldis.2020.12.024Best OA location URL: http://www.prd-journal.com/article/S135380202100016X/pdfCitation Count: 84
- Author response to comment on “The association between pain and impulse control behaviours in Parkinson's disease”2021RESTRICTEDTitle: Author response to comment on “The association between pain and impulse control behaviours in Parkinson's disease”Journal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 83Issue #:Start Page: 128End Page: 129Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.01.011Citation Count: 0
- White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's disease2021RESTRICTEDTitle: White matter hyperintensities mediate the impact of amyloid ß on future freezing of gait in Parkinson's diseaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 85Issue #:Start Page: 95End Page: 101Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.02.031Citation Count: 20
-
OPENTitle: Effects of angiotensin type 1 receptor antagonists on Parkinson's disease progression: An exploratory study in the PPMI databaseJournal Name: Parkinsonism & Related DisordersPublisher: Elsevier BVVol: 86Issue #:Start Page: 34End Page: 37Publication Date:Open Access(OA) Status: OPENLicense:DOI - Digital Object Identifier: 10.1016/j.parkreldis.2021.03.007Best OA location URL: https://repositorio.uca.edu.ar/handle/123456789/11625Citation Count: 21
- Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's disease2021RESTRICTEDTitle: Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson's diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 186Issue #:Start Page: 108465End Page: 108465Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2021.108465Citation Count: 19
- Special Issue on new therapeutic approaches to Parkinson disease2022RESTRICTEDTitle: Special Issue on new therapeutic approaches to Parkinson diseaseJournal Name: NeuropharmacologyPublisher: Elsevier BVVol: 208Issue #:Start Page: 108998End Page: 108998Publication Date:Open Access(OA) Status: RESTRICTEDLicense:DOI - Digital Object Identifier: 10.1016/j.neuropharm.2022.108998Citation Count: 5